Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc's stock outlook is bolstered by its attractive current valuation and significant potential for upside, as reflected in the positive net present value (NPV) analysis despite adjustments to price targets. Recent reports of interim data indicate meaningful improvements in lung function and biomarkers related to fibrosis resolution, underscoring the therapeutic promise of GRI-0621 in treating serious inflammatory and fibrotic diseases. Additionally, the company's commitment to well-tolerated treatment regimens, as evidenced by meeting primary and secondary study endpoints, enhances confidence in the safety and efficacy of its innovative pipeline, further supporting a positive long-term investment perspective.

Bears say

GRI Bio Inc reported a net loss of $3.4 million with an earnings per share (EPS) of $(1.28), which fell short of both internal estimates and consensus expectations. Furthermore, the company's financial performance has shown a pattern of exceeding loss estimates, raising concerns about its ability to achieve profitability in the near term. Key risks identified include balance sheet and liquidity challenges, potential failures in clinical trials, and obstacles in regulatory approval and product commercialization, all of which contribute to a negative outlook on GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.